RxDoctor Payments Data

Christina Jones, MD

Family Medicine · Bronx, NYNPI 1194762104

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total. That places this record below the midpoint for family medicine clinicians in NY, where the typical reported total is $355.

$210in general payments, 2019–2025

Across 10 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$61
  • Lilly USA, LLC$35
  • Astellas Pharma US Inc$25
  • Viiv Healthcare Company$24
  • Shield Therapeutics Inc$19
  • GSK$16
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$210 in reported general payments places this provider in the 35th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$4,150
Medicare patients
27
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$15,247
JardianceEmpagliflozin11$11,094
Atorvastatin Calcium45$518
Metoprolol Succinate11$343
Albuterol Sulfate HfaAlbuterol Sulfate13$321
Lisinopril22$126
Losartan Potassium15$124
Ondansetron OdtOndansetron27$123
Metformin Hcl19$106
Trazodone Hcl13$99
Amlodipine Besylate21$96
Hydrochlorothiazide13$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$15,24712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →